• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脑肿瘤中组织型纤溶酶原激活剂含量的生物学意义。

Biological significance of tissue plasminogen activator content in brain tumors.

作者信息

Sawaya R, Rämö O J, Shi M L, Mandybur G

机构信息

Department of Neurosurgery, MD Anderson Cancer Center, Houston, Texas.

出版信息

J Neurosurg. 1991 Mar;74(3):480-6. doi: 10.3171/jns.1991.74.3.0480.

DOI:10.3171/jns.1991.74.3.0480
PMID:1899696
Abstract

Fresh brain-tumor samples were obtained at operation and analyzed for their content of tissue type plasminogen activator (tPA) using an activity assay (gel chromatography zymogram) and an enzyme-linked immunospecific assay. The specimens were taken from 23 glioblastomas, 35 metastatic tumors, 42 meningiomas, 16 low-grade gliomas, and seven acoustic neurinomas; seven specimens were from normal brain. A strong correlation was found between the results of the two assays (r = 0.77, p less than 0.0001). There was a threefold difference in the tPA content of the benign tumors as compared to malignant tumors (p = 0.0006), the latter having less tPA. Histologically benign meningiomas contained higher tPA than malignant meningiomas (p = 0.01); however, the difference between low-grade gliomas and high-grade gliomas was less evident. Overall regression analysis data have shown an inverse relationship between the tissue content in tPA and the presence and degree of tumor necrosis and peritumoral brain edema (p = 0.004 and p = 0.0004, respectively). This finding was most consistent in the glioblastoma group where the correlation coefficient values were r = 0.53 and r = -0.55, respectively. There was no significant correlation between the tissue tPA content and the age and sex, steroid use, or plasma tPA of the patients or the duration of symptoms. In summary, this is the first demonstration of tPA in a large series of human brain tumors and in normal brain. The differences observed have clear biological significance and, although the source of tPA in tumor tissue is still unknown, a relative reduction in tPA in tumor tissue may play an integral role in the development of tissue necrosis and tissue edema. The lack of tPA in tumor necrosis was not due to tissue destruction and cell death since urokinase was readily detectable in that tissue.

摘要

新鲜脑肿瘤样本于手术时获取,并使用活性测定法(凝胶色谱酶谱法)和酶联免疫特异性测定法分析其组织型纤溶酶原激活剂(tPA)含量。样本取自23例胶质母细胞瘤、35例转移性肿瘤、42例脑膜瘤、16例低级别胶质瘤和7例听神经瘤;7个样本来自正常脑组织。两种测定结果之间存在强相关性(r = 0.77,p小于0.0001)。良性肿瘤的tPA含量与恶性肿瘤相比存在三倍差异(p = 0.0006),后者的tPA含量较少。组织学上良性的脑膜瘤比恶性脑膜瘤含有更高的tPA(p = 0.01);然而,低级别胶质瘤和高级别胶质瘤之间的差异不太明显。总体回归分析数据显示tPA的组织含量与肿瘤坏死及瘤周脑水肿的存在和程度呈负相关(分别为p = 0.004和p = 0.0004)。这一发现在胶质母细胞瘤组中最为一致,其中相关系数值分别为r = 0.53和r = -0.55。组织tPA含量与患者的年龄、性别、类固醇使用情况、血浆tPA或症状持续时间之间无显著相关性。总之,这是首次在大量人类脑肿瘤及正常脑组织中证实tPA的存在。观察到的差异具有明确的生物学意义,尽管肿瘤组织中tPA的来源仍不清楚,但肿瘤组织中tPA的相对减少可能在组织坏死和组织水肿的发展中起重要作用。肿瘤坏死中缺乏tPA并非由于组织破坏和细胞死亡,因为在该组织中很容易检测到尿激酶。

相似文献

1
Biological significance of tissue plasminogen activator content in brain tumors.脑肿瘤中组织型纤溶酶原激活剂含量的生物学意义。
J Neurosurg. 1991 Mar;74(3):480-6. doi: 10.3171/jns.1991.74.3.0480.
2
[A plasminogen regulation system in brain tumors].[脑肿瘤中的纤溶酶原调节系统]
Zh Vopr Neirokhir Im N N Burdenko. 2017;81(2):22-27. doi: 10.17116/neiro201781222-27.
3
Tissue plasminogen activator expression in meningiomas and glioblastomas.组织型纤溶酶原激活剂在脑膜瘤和胶质母细胞瘤中的表达。
Clin Neurol Neurosurg. 2005 Jun;107(4):296-300. doi: 10.1016/j.clineuro.2004.09.010.
4
Plasminogen activator inhibitor-1 in brain tumors: relation to malignancy and necrosis.脑肿瘤中的纤溶酶原激活物抑制剂-1:与恶性程度和坏死的关系。
Neurosurgery. 1995 Feb;36(2):375-80; discussion 380-1. doi: 10.1227/00006123-199502000-00018.
5
Urokinase plasminogen activator is elevated in human astrocytic gliomas relative to normal adjacent brain.与相邻正常脑组织相比,人星形胶质细胞瘤中尿激酶型纤溶酶原激活剂水平升高。
Oncol Res. 1993;5(10-11):409-14.
6
Correlation of tumor plasminogen activator with peritumoral cerebral edema. A CT and biochemical study.肿瘤纤溶酶原激活剂与瘤周脑水肿的相关性:一项CT及生化研究
J Neurosurg. 1987 May;66(5):729-33. doi: 10.3171/jns.1987.66.5.0729.
7
Prognostic significance of proteolytic enzymes in human brain tumors.蛋白水解酶在人脑肿瘤中的预后意义。
J Neurooncol. 1994;22(2):101-10. doi: 10.1007/BF01052886.
8
Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.乳腺癌患者血浆和肿瘤组织提取物中纤溶酶原激活物系统成分的测定:欧洲癌症研究与治疗组织(EORTC)受体与生物标志物小组合作项目
Oncol Rep. 2005 Jul;14(1):235-9.
9
Immunohistochemical demonstration of alpha-1-proteinase inhibitor in brain tumors.脑肿瘤中α-1蛋白酶抑制剂的免疫组织化学证明
Cancer. 1987 Aug 15;60(4):804-9. doi: 10.1002/1097-0142(19870815)60:4<804::aid-cncr2820600416>3.0.co;2-u.
10
Immunohistochemical localization of plasminogen activator inhibitor type 1 in human brain tumors.人脑肿瘤中1型纤溶酶原激活物抑制剂的免疫组织化学定位
J Neuropathol Exp Neurol. 1994 May;53(3):256-62. doi: 10.1097/00005072-199405000-00006.

引用本文的文献

1
ProBDNF and its receptors are upregulated in glioma and inhibit the growth of glioma cells in vitro.ProBDNF 及其受体在神经胶质瘤中上调,并抑制神经胶质瘤细胞在体外的生长。
Neuro Oncol. 2013 Aug;15(8):990-1007. doi: 10.1093/neuonc/not039. Epub 2013 Apr 10.
2
The Platelet Function Analyzer (PFA-100) as a Screening Tool in Neurosurgery.血小板功能分析仪(PFA - 100)在神经外科作为一种筛查工具
ISRN Hematol. 2012;2012:839242. doi: 10.5402/2012/839242. Epub 2012 Aug 8.
3
Loss of inhibitor of growth (ING-4) is implicated in the pathogenesis and progression of human astrocytomas.
生长抑制剂(ING-4)的缺失与人类星形细胞瘤的发病机制和进展有关。
Brain Pathol. 2010 Mar;20(2):490-7. doi: 10.1111/j.1750-3639.2009.00325.x. Epub 2009 Aug 6.
4
Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma.中枢神经系统恶性肿瘤中的血管内血栓形成:在星形细胞瘤进展为胶质母细胞瘤中的潜在作用。
Brain Pathol. 2008 Apr;18(2):164-71. doi: 10.1111/j.1750-3639.2007.00108.x. Epub 2007 Dec 17.
5
The antiangiogenic agent Neovastat (AE-941) stimulates tissue plasminogen activator activity.抗血管生成药物Neovastat(AE - 941)可刺激组织纤溶酶原激活物活性。
Invest New Drugs. 2004 Jan;22(1):17-26. doi: 10.1023/b:drug.0000006171.54078.3d.
6
Multi-agent cytostatic treatment of 'low-grade' gliomas.“低级别”胶质瘤的多药联合细胞抑制治疗
Curr Oncol Rep. 2000 Sep;2(5):454-62. doi: 10.1007/s11912-000-0066-0.
7
Prognostic significance of preoperative MRI scans in glioblastoma multiforme.术前磁共振成像扫描在多形性胶质母细胞瘤中的预后意义
J Neurooncol. 1996 Jan;27(1):65-73. doi: 10.1007/BF00146086.
8
Cerebral oedema associated with WHO-I, WHO-II, and WHO-III-meningiomas: correlation of clinical, computed tomographic, operative and histological findings.与世界卫生组织I级、II级和III级脑膜瘤相关的脑水肿:临床、计算机断层扫描、手术及组织学检查结果的相关性
Acta Neurochir (Wien). 1993;125(1-4):34-40. doi: 10.1007/BF01401825.
9
Expression of 72 kDa type IV collagenase and invasion activity of human glioma cells.人胶质瘤细胞中72kDa IV型胶原酶的表达及侵袭活性
Clin Exp Metastasis. 1994 Jul;12(4):296-304. doi: 10.1007/BF01753836.
10
Role of plasminogen activator and of 92-KDa type IV collagenase in glioblastoma invasion using an in vitro matrigel model.使用体外基质胶模型研究纤溶酶原激活剂和92-kDa IV型胶原酶在胶质母细胞瘤侵袭中的作用。
J Neurooncol. 1994;18(2):129-38. doi: 10.1007/BF01050419.